A citation-based method for searching scientific literature

C Robert, K D Lewis, R Gutzmer, D Stroyakovskiy, H Gogas, S Protsenko, R P Pereira, T Eigentler, P Rutkowski, L Demidov, I Caro, H Forbes, K Shah, Y Yan, H Li, G A McArthur, P A Ascierto. Ann Oncol 2022
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo A Ascierto, Paul D Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux,[...]. J Clin Oncol 2022
8
100

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Rosalie Stephens, Inge Marie Svane,[...]. J Immunother Cancer 2020
43
100

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
Reinhard Dummer, Jan C Brase, James Garrett, Catarina D Campbell, Eduard Gasal, Matthew Squires, Daniel Gusenleitner, Mario Santinami, Victoria Atkinson, Mario Mandalà,[...]. Lancet Oncol 2020
53
100

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Caroline Robert, Antoni Ribas, Jacob Schachter, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona M McNeil, Michal Lotem,[...]. Lancet Oncol 2019
434
100

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.
Dennie T Frederick, Adriano Piris, Alexandria P Cogdill, Zachary A Cooper, Cecilia Lezcano, Cristina R Ferrone, Devarati Mitra, Andrea Boni, Lindsay P Newton, Chengwen Liu,[...]. Clin Cancer Res 2013
671
100

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Ralf Gutzmer, Daniil Stroyakovskiy, Helen Gogas, Caroline Robert, Karl Lewis, Svetlana Protsenko, Rodrigo P Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov,[...]. Lancet 2020
198
100

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, Keith T Flaherty, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova,[...]. Eur J Cancer 2020
79
100

An Altered Ratio of CD4+ And CD8+ T Lymphocytes in Cervical Cancer Tissues and Peripheral Blood – A Prognostic Clue?
Diptimoy Das, Basab Sarkar, Sandip Mukhopadhyay, Chandranath Banerjee, Supreeti Biswas Mondal. Asian Pac J Cancer Prev 2018
16
50


CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.
Kayoko Waki, Kouichiro Kawano, Naotake Tsuda, Nobukazu Komatsu, Akira Yamada. Cancer Sci 2020
5
50

TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
F Stephen Hodi, Jedd D Wolchok, Dirk Schadendorf, James Larkin, Georgina V Long, Xiaozhong Qian, Abdel Saci, Tina C Young, Sujaya Srinivasan, Han Chang,[...]. Cancer Immunol Res 2021
11
50

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.
James S Wilmott, Georgina V Long, Julie R Howle, Lauren E Haydu, Raghwa N Sharma, John F Thompson, Richard F Kefford, Peter Hersey, Richard A Scolyer. Clin Cancer Res 2012
478
50

Immunological effects of BRAF+MEK inhibition.
Paolo A Ascierto, Reinhard Dummer. Oncoimmunology 2018
38
50

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn,[...]. Science 2018
916
50

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma.
Inês Pires da Silva, Kevin Y X Wang, James S Wilmott, Jeff Holst, Matteo S Carlino, John J Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann,[...]. Clin Cancer Res 2019
40
50

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Adil I Daud, Jedd D Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S Weber, Antoni Ribas, F Stephen Hodi, Anthony M Joshua, Richard Kefford, Peter Hersey,[...]. J Clin Oncol 2016
396
50

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
J H Lee, G V Long, S Boyd, S Lo, A M Menzies, V Tembe, A Guminski, V Jakrot, R A Scolyer, G J Mann,[...]. Ann Oncol 2017
181
50

Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade.
Charlotte E Ariyan, Mary Sue Brady, Robert H Siegelbaum, Jian Hu, Danielle M Bello, Jamie Rand, Charles Fisher, Robert A Lefkowitz, Kathleen S Panageas, Melissa Pulitzer,[...]. Cancer Immunol Res 2018
83
50

The Molecular Signatures Database (MSigDB) hallmark gene set collection.
Arthur Liberzon, Chet Birger, Helga Thorvaldsdóttir, Mahmoud Ghandi, Jill P Mesirov, Pablo Tamayo. Cell Syst 2015
50

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, Robert J Orlowski, Rosemarie Mick, Bertram Bengsch, Sasikanth Manne, Wei Xu, Shannon Harmon, Josephine R Giles, Brandon Wenz,[...]. Nature 2017
835
50

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko,[...]. N Engl J Med 2019
473
50

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Chad Tang, James W Welsh, Patricia de Groot, Erminia Massarelli, Joe Y Chang, Kenneth R Hess, Sreyashi Basu, Michael A Curran, Maria E Cabanillas, Vivek Subbiah,[...]. Clin Cancer Res 2017
195
50

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
50

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Mahrukh M Syeda, Jennifer M Wiggins, Broderick C Corless, Georgina V Long, Keith T Flaherty, Dirk Schadendorf, Paul D Nathan, Caroline Robert, Antoni Ribas, Michael A Davies,[...]. Lancet Oncol 2021
26
50

Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, Michelle Casey, Georgina V Long, Dirk Schadendorf, Keith Flaherty, Richard Kefford, Axel Hauschild, Patrick Hwu,[...]. Clin Cancer Res 2016
142
50

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer,[...]. N Engl J Med 2019
50

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
Paolo A Ascierto, Brigitte Dréno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandalà, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas,[...]. Clin Cancer Res 2021
14
50

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, Mario Mandalà, Paul D Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf,[...]. Nat Med 2020
44
50

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
Rosalin Mishra, Hima Patel, Samar Alanazi, Mary Kate Kilroy, Joan T Garrett. Int J Mol Sci 2021
21
50

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
Klaus P Hoeflich, Mark Merchant, Christine Orr, Jocelyn Chan, Doug Den Otter, Leanne Berry, Ian Kasman, Hartmut Koeppen, Ken Rice, Nai-Ying Yang,[...]. Cancer Res 2012
186
50


Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma.
Chengli Song, Lina Wang, Qiang Xu, Kai Wang, Dan Xie, Zhe Yu, Kui Jiang, Lujian Liao, John R Yates, Jiing-Dwan Lee,[...]. Sci Rep 2017
17
50


Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.
Benjamin D Hopkins, Chantal Pauli, Xing Du, Diana G Wang, Xiang Li, David Wu, Solomon C Amadiume, Marcus D Goncalves, Cindy Hodakoski, Mark R Lundquist,[...]. Nature 2018
284
50

The Raf/MEK/ERK pathway: new concepts of activation.
C Peyssonnaux, A Eychène. Biol Cell 2001
558
50

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Marcel A Deken, Jules Gadiot, Ekaterina S Jordanova, Ruben Lacroix, Melissa van Gool, Paula Kroon, Cristina Pineda, Marnix H Geukes Foppen, Richard Scolyer, Ji-Ying Song,[...]. Oncoimmunology 2016
89
50


AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B.
Jia Xu, Xufen Yu, Tiphaine C Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M Cahuzac, Li Wang, Ling Xie,[...]. Cancer Discov 2021
10
50

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
Cedric Leroy, Pedro Ramos, Karen Cornille, Debora Bonenfant, Christine Fritsch, Hans Voshol, Mohamed Bentires-Alj. Breast Cancer Res 2016
34
50

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Vanessa S Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C Pagano, Poulikos I Poulikakos, Maurizio Scaltriti, Elizabeth Moskatel, José Baselga, Sylvie Guichard, Neal Rosen. Cancer Discov 2011
324
50

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
F André, E M Ciruelos, D Juric, S Loibl, M Campone, I A Mayer, G Rubovszky, T Yamashita, B Kaufman, Y-S Lu,[...]. Ann Oncol 2021
86
50


Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Lisa Haas, Anais Elewaut, Camille L Gerard, Christian Umkehrer, Lukas Leiendecker, Malin Pedersen, Izabela Krecioch, David Hoffmann, Maria Novatchkova, Mario Kuttke,[...]. Nat Cancer 2021
23
50

Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors.
Emilie Clement, Hiroyuki Inuzuka, Naoe T Nihira, Wenyi Wei, Alex Toker. Sci Signal 2018
30
50

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Deborah A Knight, Shin Foong Ngiow, Ming Li, Tiffany Parmenter, Stephen Mok, Ashley Cass, Nicole M Haynes, Kathryn Kinross, Hideo Yagita, Richard C Koya,[...]. J Clin Invest 2016
9
50

Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.
Chi Yan, Nabil Saleh, Jinming Yang, Caroline A Nebhan, Anna E Vilgelm, E Premkumar Reddy, Joseph T Roland, Douglas B Johnson, Sheau-Chiann Chen, Rebecca L Shattuck-Brandt,[...]. Mol Cancer 2021
4
50

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Alison M Schram, Leena Gandhi, Monica M Mita, Lars Damstrup, Frank Campana, Manuel Hidalgo, Enrique Grande, David M Hyman, Rebecca S Heist. Br J Cancer 2018
40
50


A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma.
Alain Patrick Algazi, Julia Rotow, Christian Posch, Susana Ortiz-Urda, Alyson Pelayo, Pamela N Munster, Adil Daud. Pigment Cell Melanoma Res 2019
12
50

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
S Chandarlapaty, M Scaltriti, P Angelini, Q Ye, M Guzman, C A Hudis, L Norton, D B Solit, J Arribas, J Baselga,[...]. Oncogene 2010
93
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.